Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer

M. Bottosso, F. Mosele, S. Michiels, P. H. Cournède, S. Dogan, C. Labaki, F. André

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)

    Abstract

    Tumor heterogeneity represents a major challenge in breast cancer, being associated with disease progression and treatment resistance. Precision medicine has been extensively applied to dissect tumor heterogeneity and, through a deeper molecular understanding of the disease, to personalize therapeutic strategies. In the last years, technological advances have widely improved the understanding of breast cancer biology and several trials have been developed to translate these new insights into clinical practice, with the ultimate aim of improving patients’ outcomes. In the era of molecular oncology, genomics analyses and other methodologies are shaping a new treatment algorithm in breast cancer care. In this manuscript, we review the main steps of precision medicine to predict drug sensitivity in breast cancer from a translational point of view. Genomic developments and their clinical implications are discussed, along with technological advancements that could broaden precision medicine applications. Current achievements are put into perspective to provide an overview of the state-of-art of breast cancer precision oncology as well as to identify future research directions.

    Original languageEnglish
    Article number102247
    JournalESMO Open
    Volume9
    Issue number3
    DOIs
    Publication statusPublished - 1 Mar 2024

    Keywords

    • biomarkers
    • breast cancer
    • genomics
    • precision medicine
    • targeted therapy

    Cite this